Abstract
Introduction/BackgroundBRCA1/2 mutations, integral drivers of homologous recombination deficiency (HRD), are observed in up to 15–25% of patients with primary advanced high-grade ovarian cancer (OC). Maintenance treatment with PARPi has significantly...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
